Evidence map›Paper›PMID 38138508›Full record

ReviewMolecules (Basel, Switzerland)2023

Bench to Bedside Development of [

Amarnath Challapalli, Tara D Barwick, Suraiya R Dubash, Marianna Inglese, Matthew Grech-Sollars, Kasia Kozlowski, Henry Tam, Neva H Patel, Mathias Winkler, Penny Flohr and 6 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Amarnath ChallapalliDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK.ORCID 0000-0002-3683-9583
Tara D BarwickDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK.
Suraiya R DubashDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK.
Marianna IngleseDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK.
Matthew Grech-SollarsDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK.ORCID 0000-0003-3881-4870
Kasia KozlowskiDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK.
Henry TamDepartment of Radiology & Nuclear Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.
Neva H PatelDepartment of Radiology & Nuclear Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.
Mathias WinklerDepartment of Urology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London W6 8RF, UK.
Penny FlohrDivision of Clinical Studies, The Institute of Cancer Research and Royal Marsden Hospital, Cotswold Road, Sutton SM2 5NG, UK.
Azeem SaleemInvicro, A Konica Minolta Company, Burlington Danes Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
Amit BahlDepartment of Clinical Oncology, Bristol Haematology and Oncology Center, Horfield Road, Bristol BS2 8ED, UK.
Alison FalconerDepartment of Urology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London W6 8RF, UK.
Johann S De BonoDivision of Clinical Studies, The Institute of Cancer Research and Royal Marsden Hospital, Cotswold Road, Sutton SM2 5NG, UK.
Eric O AboagyeDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK.ORCID 0000-0003-2276-6771
Stephen MangarDepartment of Urology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London W6 8RF, UK.ORCID 0000-0002-3655-2830
Imperial College Healthcare NHS Trust · GBHammersmith Hospital · GBAt Bristol · GBInstitute of Cancer Research · GBUniversity of Hull · GB

Funding

Cancer Research UK 28680
6 · The paper itself

Abstract

Malignant transformation is characterised by aberrant phospholipid metabolism of cancers, associated with the upregulation of choline kinase alpha (CHKα). Due to the metabolic instability of choline radiotracers and the increasing use of late-imaging protocols, we developed a more stable choline radiotracer, [

Indexed as

CholineProstatic NeoplasmsHumansMalePositron-Emission TomographyPositron Emission Tomography Computed TomographyRadiometryCholine[18F]Fluoromethyl-(1,2-2H4)cholinecell membrane metabolismcholinedosimetryin vitroin vivometastatic castrate-resistant prostate cancerpositron emission tomography

Identifiers

PMID38138508
PMCPMC10745874
OpenAlexW4389545707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.